anti-CD70 CAR NK cell therapy (University of Antwerp/Argenx)

N/A

Report date: 2025/03/14 16:48:21

Base Information

Drug Nameanti-CD70 CAR NK cell therapy (University of Antwerp/Argenx)
Drug Alias NameIL-15-armored CD70-directed CAR NK-92 cells
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionInterleukin-15 receptors agonistsCD70 antigen modulators
TargetsCD70 antigenInterleukin-15 receptors
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Antwerp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of AntwerpArgenx BV
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A